Repositioning Candidate Details
| Candidate ID: | R0774 |
| Source ID: | DB05339 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MN-305 |
| Synonyms: | -- |
| Molecular Formula: | C19H22ClNO5 |
| SMILES: | Cl.C(CNC[C@H]1COC2=CC=CC=C2O1)COC1=CC2=C(OCO2)C=C1 |
| Structure: |
|
| DrugBank Description: | MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD). |
| CAS Number: | -- |
| Molecular Weight: | 379.835 |
| DrugBank Indication: | Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects. |
| Targets: | 5-hydroxytryptamine receptor 1A |
| Inclusion Criteria: | Indication associated |
